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Faecal immunochemical tests for haemoglobin (FIT) are
now regarded as the best non-invasive investigation for
screening asymptomatic individuals for the presence of
colorectal cancer (CRC) [1]. They are now used in oppor-
tunistic and programmatic screening all over theworld. FIT
are also used in surveillance programmes for patients
following removal of polyps [2]. In addition, the evidence
has grown rapidly over recent years that FIT, in conjunc-
tion with symptoms and clinical judgement, provide a very
useful tool in deciding which patients presenting in pri-
mary care with lower bowel symptoms will benefit most
from further investigation, usually bowel visualisation [3].
Although FIT are available as qualitative and quanti-
tative examinations [4], the latter give numerical estimates
of faecal haemoglobin concentrations (f-Hb). These are
now favoured in all three of the clinical settings in which
FIT are of value This is especially relevant in the current
COVID-19 pandemic, in which f-Hb have become widely
recommended by governments, as well as professional
bodies and local health organisations, for use in prioritis-
ing the further investigation of participants in screening
and patients presenting with symptoms, when they have
f-Hb greater than the threshold f-Hb used to recommend
referral [5]. Numerical threshold f-Hb are used, usually
nationally or at least regionally, for the interpretation of
FIT results in all clinical settings, particularly since
population-based reference values are inappropriate [6]. In
consequence, good examination quality and rigorous
performance of examinations are both required. The
International Organization for Standardization (ISO)
15189:2012 specifies requirements for quality and compe-
tence in medical laboratories [7].
Internal quality control
ISO 15189, section 5.6.2.2, states: Quality control materials:
The laboratory shall use quality controlmaterials that react
to the examining system in amanner as close as possible to
patient samples. It is noted that the laboratory should
choose concentrations of control materials, wherever
possible, especially at or near clinical decision values,
which ensure the validity of decisions made. Use of inde-
pendent third party control materials should be consid-
ered, either instead of, or in addition to, any control
materials supplied by the reagent or instrument manufac-
turer. However, despite these laudable ideals, haemoglo-
bin (Hb) in faeces is unstable and faecal based matrices for
internal quality control (IQC) materials are probably un-
realistic. In addition, it has been recently noted that third
party ICQ materials are lacking [3].
A possible strategy to overcome this latter deficiency
has nowbeen examined [8]. The study assessedwhether the
two or three IQC materials available from each of the four
manufacturers of quantitative FIT systems, marketed in the
United Kingdom (UK) for ongoing evaluation of their own
systems, were compatible with the other three systems. This
was achieved by quantitative estimation of within-run and
between-run imprecision. Interestingly, all results were re-
ported without flagged errors on all the FIT systems, which
supports the concept that transferability of the IQCmaterials
between systems is indeed possible. This seems logical
given that these IQC materials are either liquid or recon-
stituted lyophilised Hb solutions. There is an obvious limi-
tation to this strategy in that the mean f-Hb found on
examinations of each IQCmaterial were different from those
originally assigned by each manufacturer for their own FIT
system. However, this is unsurprising given that there is
currently no international standardisation or harmonisation
of FIT, the methods are based on polyclonal antibodies, use
different calibration techniques, are traceable to different
primary reference materials and do not have identical
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examination performance characteristics [9]. Despite this, it
was concluded that, ifmanufacturers werewilling tomarket
their IQC materials independently of their FIT systems, the
potential exists for third party IQC materials for FIT to be
widely available.
External quality assessment
ISO 15189, section 5.6.3.1 states: The laboratory shall
participate in an interlaboratory comparison programme(s)
(such as an external quality assessment [EQAS] programme
or proficiency testing programme) appropriate to the ex-
amination and interpretations of examination results. The
laboratory shall monitor the results of the interlaboratory
comparison programme(s) and participate in the imple-
mentation of corrective actions when predetermined per-
formance criteria are not fulfilled. However, following a
review of the existing challenges and constraints, Godber
et al. did state that the organisers of EQAS for FIT havemany
difficulties in providing appropriate materials [3].
In addition to assessing transferability of IQCmaterials
across FIT systems discussed above [8] and comparing the
examination performance characteristics of four FIT sys-
tems [9], the research group have studied this aspect of the
quality assurance of quantitative FIT. The rationale for the
study was that, since EQAS are being established world-
wide to support FIT examinations, the suitability of the
materials currently provided by commercially available
EQAS should be assessed [10]. Further, the EQAS chal-
lenges available for FIT do come in a variety of formats,
each unique to the individual EQAS, which might make it
difficult for medical laboratories to decide in which one or
more EQAS to participate. For the study, EQAS organisers
provided one or more materials with the following
matrices: Hb spiked artificial faecal like matrix sent to
participating laboratories for loading into FIT specimen
collection devices, Hb spiked artificial faecal like matrix
pre-loaded into FIT specimen collection devices by the
EQAS organisers and then sent to participating labora-
tories, diluted Hb directly injected into the appropriate FIT
system specimen collection devices by the EQAS orga-
nisers, Hb spiked liquid provided either lyophilised for
reconstitution by the participating medical laboratory, or
liquid ready to use after being portioned into system cups
for direct sampling on the FIT system. The examinations
were performed on the same four FIT systems used in the
study of IQCmaterials [8] and previously evaluated [9]. The
imprecision found on examination of samples with a faecal
like matrix had a higher median CV (12.4–19.0%) when
compared to those from samples with liquid matrices
(0.8–2.3%). The range of CV was also higher for samples
from faecal like matrix EQAS compared to liquid samples.
Although samples from participants in screening and
patientswithsymptomsarrive in themedical laboratoryafter
collection into the appropriate specimen collection devices,
it was the opinion of the authors that it is not necessary for
EQAS materials to be provided as a faecal like matrix. The
rationale was that faecal like matrices, whilst clearly more
consistent with participant or patient samples, are prone to
pre-examination variation and so do not assess the exami-
nation performance characteristics of a FIT system. More-
over, aproblemwith sampleswith faecal likematrices is that
it isunclearwhetheranydifferencesobserved fromthe target
values are due to pre-examination or examination variation.
Samples with liquid matrices are not prone to pre-
examination variation and were considered better able to
assess the examination performance of a FIT system.
Discussion
It has been shown that the use of IQCmaterials from one FIT
system manufacturer as third party controls for other sys-
tems seems feasible [8]. However, several questions remain
unresolved. The major issue is that, at present, medical
laboratories would have to assign the f-Hb for the particular
FIT system used and set the criteria for acceptance or
rejection of analyses. Leading third party IQC material
manufacturers assign target values using data from inde-
pendent laboratories. If independent target f-Hb data were
unavailable for the FIT system used, then the IQC material
cannot really be termed third party.Wouldmanufacturers of
FIT systems procure assignment of target values for their
own IQC materials for other manufacturers’ systems using
independent laboratories? Although available FIT systems
give different results, are the differences consistent over the
measurement ranges of the systems so that factors could be
applied to assign target values by simple multiplication of
the manufacturer assigned f-Hb? Would such factors be
consistent overdifferent lots of the critical antibody reagent?
Could the target f-Hb, appropriate to the decision threshold,
be modified by diluting liquid IQC materials, or using
different volumes of diluent for lyophilised IQC materials?
Further clarification of these issues seems warranted.
The application of currently available EQAS across
four FIT systems was also investigated [10]. Results of
EQAS challenges usually give data on comparative bias
between systems since the traditional view is that, while
IQC monitors the imprecision of examinations (and also
gives information on sudden or gradual shifts in perfor-
mance), EQAS should be providing an assessment of bias
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with respect to the same and other methods. However, the
authors decided, due to the lack of a suitable reference
material and standardisation of FIT methods, to perform
this study on imprecision. The differences between the f-Hb
found using different FIT systems requires further study
and documentation. The results from EQAS could greatly
assist in clarification of this important facet of FIT.
The publications discussed here [8, 10] provide further
interesting insights to improve the state-of-the-art of
testing for the presence of Hb in faeces: further studies are
required to continue this work. Thankfully, the Working
Group on FIT of the Scientific Division of the International
Federation of Clinical Chemistry and Laboratory Medicine
are actively pursuing strategies to improve the harmo-
nisation of FIT systems.
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